Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
M. Werner-Klein, A. Grujovic, C. Irlbeck, M. Obradovic, M. Hoffmann, H. Koerkel-Qu, X. Lu, S. Treitschke, C. Koestler, C. Botteron, K. Weidele, C. Werno, B. Polzer, S. Kirsch, M. Guzvic, , C. A. Klein
The paper identifies IL6 trans-signaling as a mechanism supporting DCC survival and outgrowth during clinical latency, with microenvironmental dependencies and PIK3CA mutations linked to metastatic progression.
bioRxiv · May 28, 2020Cancer Biology